Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 2, 2003, Pages 391-396

  Nathwani, Dilip ^a   Barlow, Gavin D ^a   Ajdukiewicz, Katherine ^a   Gray, Kirsteen ^b   Morrison, John ^a   Clift, Ben ^b   France, Anthony J ^a   Davey, Peter ^a  

^a Infection and Immunodeficiency Unit   (United Kingdom)

^b NHS TAYSIDE   (United Kingdom)

Author keywords

Bone and joint infection; Cost minimization; Linezolid; Teicoplanin; Therapeutic drug monitoring

Indexed keywords

BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; FLUCLOXACILLIN; FUSIDIC ACID; HEPARIN; LINEZOLID; METICILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; TEICOPLANIN;

AMBULATORY CARE; ARTICLE; BACTERIAL ARTHRITIS; BONE INFECTION; COST MINIMIZATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; HEALTH CARE COST; HOME CARE; HOSPITAL CARE; HUMAN; INFECTIOUS ARTHRITIS; JOINT PROSTHESIS; MEDICAL AUDIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; OUTPATIENT CARE; PROSTHESIS INFECTION; TREATMENT OUTCOME;

ACETAMIDES; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BONE DISEASES, INFECTIOUS; CLINICAL PROTOCOLS; COST CONTROL; COSTS AND COST ANALYSIS; GREAT BRITAIN; HUMANS; JOINT DISEASES; OXAZOLIDINONES; RIFAMPIN; TEICOPLANIN;

EID: 0037323823     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg061     Document Type: Article

References (30)

1. Lew, D. P. & Waldvogel, F. A. (1997). Osteomyelitis. New England Journal of Medicine 336, 999-1007.
2. Virk, A. & Osman, D. R. (2001). Prosthetic joint infection. Current Treatment Options in Infectious Diseases 3, 287-300.
3. Sculco, T. P. (1993). The economic impact of infected total joint arthroplasty. Instructional Course Lectures 42, 349-51.
4. Waldvogel, F. A., Medoff, G. & Swartz, M. (1970). Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects (part 1). New England Journal of Medicine 282, 198-206.
5. Waldvogel, F. A., Medoff, G. & Swartz, M. N. (1970). Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects (part 2). New England Journal of Medicine 282, 260-6.
6. Waldvogel, F. A., Medoff, G. & Swartz, M. N. (1970). Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects (part 3). New England Journal of Medicine 282, 316-22.
7. Dich, V. Q., Nelson, J. D. & Haltalin, K. C. (1975) Osteomyelitis in infants and children. American Journal of Diseases of Children 129, 1273-8.
8. Bamberger, D. M., Daus, G. P. & Gerding, D. N. (1987). Osteomyelitis in the feet of diabetic patients. Long-term results, prognostic factors, and the role of antimicrobial and surgical therapy. American Journal of Medicine 83, 653-60.
9. Stengel, D., Bauwens, K., Sehouli, J., Ekkernkamp, A. & Porzsolt, F. (2001). Systematic review and meta-analysis of antibiotic therapy of bone and joint infections. Lancet Infectious Diseases 1, 175.
10. Inman, R. D., Gallegos, K. V., Brause, B. D., Redecha, P. B. & Christian, C. L. (1984). Clinical and microbial features of prosthetic joint infection. American Journal of Medicine 77, 47-53.
11. Tice, A. (2001). The use of outpatient parenteral antimicrobial therapy in the management of osteomyelitis: data from the outpatient parenteral antimicrobial therapy outcomes registries. Chemotherapy 47, Suppl., 5-16.
12. Norden, C. W., Bryant, R., Palmer, D., Montgomerie, J. Z. & Wheat, J. (1986). Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. Southern Medical Journal 79, 947-51.
13. Zimmerli, W., Widmer, A. F., Blatter, M., Frei, R. & Oshsner, P. E. (1998). Role of rifampicin for implant related staphylococcal infections. Journal of the American Association 279, 1537-41.
14. Tice, A. D. (2000). Outpatient parenteral antibiotic therapy (OPAT) in the United States: delivery models and indications for use. Canadian Journal of Infectious Disease 1, Suppl. A, 17-21.
15. Wilson, A. P. R. & Gruneberg, R. N. (1994). Use of teicoplanin in community medicine. European Journal of Clinical Microbiology and Infectious Disease 13, 701-10.
16. Nathwani, D. (1998). Non-inpatient use of teicoplanin. International Journal of Clinical Practice 52, 577-81.
17. Graninger, W., Presterl, E., Wenisch, C., Schwameis, E., Breyer, S. & Vukovich, T. (1997). Management of serious staphylococcal infections in the outpatient setting. Drugs 54, Suppl. 6, 21-8.
18. Spencer, C. M. & Bryson, H. M. (1995). Teicoplanin: a pharmacoeconomic evaluation of its use in the treatment of Gram-positive infections. Pharmacoeconomics 7, 275-374.
19. Davey, P. G., South, R. & Malek, M. (1996). Impact of glycopeptide therapy after hospital discharge on inpatient costs: a comparision of teicoplanin and vancomycin. Journal of Antimicrobial Chemotherapy 37, 623-34.
20. Clemett, D. & Markham, A. (2000). Linezolid. Drugs 59, 815-27.
21. Rana, B., Butcher, I., Grigoris, P., Murnaghan, C., Seaton, R. A. & Tobin, C. M. (2002). Linezolid penetration into osteo-articular tissues. Journal of Antimicrobial Chemotherapy 50, 747-50.
22. Bassetti, M., Biagio, A. D., Cenderello, G., Del Bono, V., Palermo, A., Cruciani, M. et al. (2001). Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA). Journal of Infection 43, 148-57.
23. Nathwani, D. & Tice, A. D. (2002). Ambulatory antimicrobial use: the value of an outcomes registry, Journal of Antimicrobial Chemotherapy 49, 149-54.
24. Harding, I., McGowan, A. P., White, L. O., Darley, E. S. & Reed, V. (2000). Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentration and outcome. Journal of Antimicrobial Chemotherapy 45, 835-41.
25. Darley, E. S. R. (2001). The clinical value of teicoplanin therapeutic drug monitoring. CPD Infection 2, 93-7.
26. Green, S. L., Maddox, J. C. & Huttenbach, E. D. (2001). Linezolid and reversible myelosuppression. Journal of the American Association 285, 1291.
27. Attassi, K., Hershberger, E., Alam, R. & Zervos, M. J. (2002). Thrombocytopenia associated with linezolid therapy. Clinical Infectious Diseases 34, 695-8.
28. Nathwani, D., Morrison, J., Seaton, R. A., France, A. J., Davey, P. & Gray, K. (1999). Outpatient and home parenteral antibiotic therapy (OHPAT): evaluation of the impact of one year's experience in Tayside. Health Bulletin 57, 332-7.
29. Wilson, A. P. R. (2000). Clinical pharmacokinetics of teicoplanin. Clinical Pharmacokinetics 39, 167-83.
30. Zyvox (linezolid) [package insert]. (2002). Pharmacia and Upjohn Company, Kalamazoo, MI, USA.